Different association of serum docosahexaenoic acid and eicosapentaenoic acid levels with atherogenic and anti-atherogenic lipoproteins in statin-treated diabetes patients

Objectives: Supplementation of purified n-3 polyunsaturated fatty acids (PUFAs), such as eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), has been shown to reduce cardiovascular risk beyond low-density lipoprotein cholesterol (LDL-C). However, regarding the circulating levels of PUFAs, despite anti-atherogenic features of EPA, there is controversy about those of DHA. In this study, we aimed to clarify the difference in the clinical association with atherogenic or anti-atherogenic lipoproteins between circulating EPA and DHA levels.